Efficacy and Safety of UGN-101 in Recurrent Patients

Withdrawn before enrolling · Phase 3

Conditions studied: Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter

In brief

This trial is designed to evaluate the efficacy and safety of UGN-101 administered to the upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit and are subsequently found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma (UTUC) at follow up (FU).

Key facts

Study ID

NCT04006691

Run by

UroGen Pharma Ltd.

People needed

0

Starts

2019-10-01

Expected to finish

2020-03-31

Last updated by the study team

2020-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA - University of California, Los Angeles — Los Angeles, California, United States
• Mayo Clinic Florida — Jacksonville, Florida, United States
• John Hopkins University — Baltimore, Maryland, United States
• Urology Center Las Vegas — Las Vegas, Nevada, United States
• Sheba Medical Center — Ramat Gan, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.